Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0F4VW
|
||||
| Former ID |
DIB001109
|
||||
| Drug Name |
SRX-246
|
||||
| Synonyms |
AVN-518; SRX-246-HCI; Vasopressin V1a antagonist (capsule/oral, stress-related affective illness/anxiety), Azevan Pharmaceutoicals
|
||||
| Indication | Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] | Phase 1/2 | [1] | ||
| Company |
Azevan Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
C(=O)(N1CCC(CC1)N1CCCCC1)C[C@@H](N1[C@@H]([C@H](N2[C@@H<br />](c3ccccc3)COC2=O)C1=O)/C=C/c1ccccc1)C(=O)N[C@@H](c1ccc<br />cc1)C
|
||||
| Target and Pathway | |||||
| Target(s) | Vasopressin V1a receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023656) | ||||
| REF 2 | Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-43. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.